ESR1 and breast carcinoma: A preliminary evaluation of the novel compounds in ER+/PR+MCF-7 breast cancer cells identified compound 22b as a potent antiproliferative compound (IC50 = 0.385 μM) in MCF-7 breast cancer cells (ER+/PR+) and 0.765 μM in triple-negative MDA-MB-231 breast cancer cells.